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Within the family of endogenous gasotransmitters, nitric oxide (NO) is the smallest gaseous intercellular messenger involved in the
modulation of several processes, such as blood flow and platelet aggregation control, essential to maintain vascular homeostasis.
NO is produced by nitric oxide synthases (NOS) and its effects are mediated by cGMP-dependent or cGMP-independent
mechanisms. Growing evidence suggests a crosstalk between the NO signaling and the occurrence of oxidative stress in the onset
and progression of vascular diseases, such as hypertension, heart failure, ischemia, and stroke. For these reasons, NO is considered
as an emerging molecular target for developing therapeutic strategies for cardio- and cerebrovascular pathologies. Several natural
derived compounds, such as polyphenols, are now proposed as modulators of NO-mediated pathways. The aim of this review is
to highlight the experimental evidence on the involvement of nitric oxide in vascular homeostasis focusing on the therapeutic
potential of targeting NO with some natural compounds in patients with vascular diseases.
1. Introduction
Since 1992, when nitric oxide (NO)was nominated “molecule
of the year” [1, 2], it continues to attract the interest of the sci-
entific community. NO is the smallest gasotransmitter, recog-
nized as an ubiquitous intercellular messenger; it is produced
by three isoforms of NO synthases (NOS): endothelial NOS
(eNOS) [3], neuronal NOS (nNOS) [4], and inducible NOS
(iNOS) [5] and mitochondrial NOS (mtNOS) [6]. All NOS
isozymes utilize L-arginine and oxygen and the reduced form
of nicotinamide-adenine-dinucleotide phosphate (NADPH)
as substrates and 6R-5,6,7,8-tetrahydro-L-biopterin (BH
4
) as
essential cofactor to generateNOandL-citrulline [7, 8].Then,
the main downstream signaling pathway carried out by the
NO is the activation of soluble guanylyl cyclase (sGC), which
in turn generates cyclic guanosine monophosphate (cGMP)
[9] (Figure 1).
In the vascular system NO modulates blood flow [10],
vascular tone [11], and platelet aggregation [12] exerting
antihypertensive, antithrombotic, and atherosclerotic effects.
It is also involved in the stimulation of the endothelial
progenitor cells (EPCs) and proliferation of the smooth
muscle cells (SMCs) [13].Therefore, an impairment in theNO
signaling is associated with the onset and perpetuation of the
main clinical condition associated to cardiovascular diseases
(CVDs) including endothelial dysfunction [14].
Given this premise, it is reasonable to consider NO as a
therapeutic target for CVDs. Indeed, several approaches have
been proposed tomodulateNOpathwayswhile preserving its
physiological role [15]. From one side, the strategy consists
in enhancing NO bioavailability, principally acting on NOS
cofactors or avoiding NO breakdown; from the other side,
different drugs act on the NO downstream signaling targets
[16].
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Figure 1: Nitric oxide generation: several stimuli induce eNOS activation and NO production in endothelial cells. NO diffusion in smooth
muscle cells is responsible for cGMP generation and vasorelaxation.
Data from epidemiological studies have suggested the
existence of a relationship between physical exercise and/or
specific diets with a reduction of CVDs prevalence and
incidence [17–20]. In addition, clinical trials and experiments
in animal models have indicated NO as the main mediator of
the beneficial effects of certain natural derived compounds,
such as the polyphenols [17, 21].
In the present review, we discuss the biochemistry and
pathophysiology of signaling pathways of NO focusing our
attention on the experimental data showing that some natural
derived compounds could be effective in the prevention and
possibly treatment of CVDs.
2. Molecular Pathways of NO
Among the isoforms of NOS, eNOS represents the main
source for the NO production in the vasculature. It is
predominantly expressed in the endothelium but it has
been also detected in kidney, human placenta, cardiomy-
ocytes, platelets, and some neurons [22]. Several endogenous
agonists, such as acetylcholine, bradykinin, and vascular
endothelial growth factor (VEGF), as well as the shear stress
induced by the blood flow, have been reported to activate
eNOS [23]. Several studies have demonstrated that the
phosphoinositide 3-kinase- (PI3K-) AKT pathway is mainly
responsible for eNOS phosphorylation at Ser1177 especially
in response to shear stress and VEGF [24–26]. Moreover,
caveolin-1, themain component of the caveolae plasmamem-
branes, has been reported as a negative regulator of eNOS
[27, 28]. Another mechanism involved in the production of
eNOS-derived NO is the activation of the 𝛽-adrenoreceptors
[29] in response to the increase of catecholamines that are
expressed at high levels in condition of oxidative stress
associated with endothelial dysfunction [30, 31].
Neuronal NOS (nNOS) is expressed in specific neurons
of the central nervous systems (CNS), as well as in the
peripheral nervous systems (PNS) and in perivascular nerve
fibers [32]. As in the case of eNOS, nNOS is responsible for
the constitutively production of NO [33]. The inducible NOS
(iNOS) is normally inactive in the vasculature [34], but its
expression and activity can be induced in many cell types
under oxidative and inflammatory stimuli; as a matter of fact
several cytokines have been detected in the endothelium, in
the media, and in the adventitia of blood vessels, as well as
in neuronal cells and hepatocytes. Moreover, it is well known
that NO produced by iNOS participates to the response of
the immune system in killing bacteria and other exogenous
compounds [35]. Several studies show the presence of a new
isoform of eNOS enzyme in mitochondria (mtNOS) [36, 37].
This fourth isoform, the mtNOS, is responsible of the NO
production in the mitochondria. It has been demonstrated
that the NO-synthesizing capacity of mtNOS is higher than
that derived from the combined activity of the all other
NOS isoforms [38]. Moreover, recent findings suggest that
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Figure 2: Decreased bioavailability of NO: oxidative stress is the
cause of endothelial dysfunction, the common feature of CVDs;
eNOS decreased activity due to different molecular pathways
reduces NO production (see text for details).
an excessive stimulation of mtNOS leads to mitochondrial
dysfunctions, which contribute to metabolic syndromes [39].
All NOS proteins are homodimers that transfer elec-
trons from NADPH to the haem in the oxygenase domain
where there are also binding sites for BH
4
, oxygen, and
L-arginine; at the haem site, the electrons are used to
reduced O
2
and to oxidize L-arginine to L-citrulline and
NO. Importantly, when oxidative stress increases, eNOS can
lose its physiological properties in a process termed “eNOS
uncoupling” [22, 40] (Figure 2). In such condition, NO reacts
with superoxide O
2
−, leading to formation of peroxynitrite
(ONOO−), potent inducers of cell death, and eNOS produces
reactive oxygen species (ROS), mainly O
2
−, rather than
NO [41]. Therefore, eNOS uncoupling not only leads to
decreasing NO bioavailability, but contributes to enhancing
the preexisting oxidative stress [42]. Different mechanisms
have been suggested to explain eNOS uncoupling; among
these, the oxidation of BH
4
to the inactive form BH
3
− by O
2
−
and ONOO− together with depletion of L-arginine plays a
prominent role [4]. In particular, the decrease of L-arginine
is caused by the upregulation of arginase isoforms (Arg
I and Arg II) expression and activity. As we will discuss
in the next sections, oxidative stress associated to eNOS
uncoupling and the changing of the eNOS phosphorylation
status (summarized in Figure 3) are characteristics of clinical
conditions commonly associated to CVDs, such as diabetes
mellitus, hypertension, atherosclerosis, and cerebral ischemia
[22, 43].
2.1. Posttranslational Modifications of NOS. NOS enzymes
are regulated by multiple interdependent mechanisms and
signaling pathways, which can be calcium-dependent and/or
calcium-independent. In particular, it has been demonstrated
that the activity of eNOS is regulated by the increase of
the cytosolic Ca2+ in endothelial cells, which leads to the
activation of calmodulin that in turn binds eNOS, thus
facilitating its function [23, 44]. Besides the increase of
intracellular calcium, eNOS activity depends also on its
phosphorylation status. In particular, It has been suggested
that the phosphorylation of NOS isoforms at Tyr81 and
Tyr657 represents a mechanism necessary to modulate the
NO production above all during shear stress [45, 46].
Indeed, the phosphorylation is the major and most
studied posttranslationalmodifications influencing the eNOS
activity. Noteworthy, while the phosphorylation of serine at
positions 617, 635, and 1179/1177 results in the activation of
the eNOS, the same change at Ser116 and Thr497 reduces its
function.
Also acetylation of the eNOS influences its activity and,
in general, acetylation/deacetylation balance represents a
crucial homeostatic mechanism mediating the response to
metabolic changes in the cell [47].
Other important posttranslational changes are acylation,
nitrosylation, glycosylation, and glutathionylation. All of
them are necessary and often interconnected in controlling
the subcellular localization and/or activity of the eNOS
and thus the NO bioavailability in response to a variety of
physiologic and pathophysiologic signals [48].
3. Physiopathological Role of NO in
the Vascular System
The role of NO in the maintenance of vascular homeostasis
is well defined and it depends on both eNOS distribution
pattern and NO production rate. Perturbation of NO sig-
naling pathways represents one of the major determinants
of endothelial dysfunction, which is characterized by the
reduction of the NO bioavailability and oxidative stress
increase with the resulting impairment of the endothelium-
dependent vasodilation [49, 50].
The NO synthesized by eNOS diffuses from endothelial
cells into the underlying SMCs in which it stimulates sGC,
thus generating cGMP, which in turn activates downstream
protein kinases. Protein kinases predominantly act onmyosin
light chain phosphatase, the enzyme that dephosphorylates
myosin light chains and leads to smooth muscle relax-
ation and vasodilatation. Moreover, NO may diffuse also
in the blood flow where it inhibits several processes nor-
mally impaired during thrombotic and atherosclerotic events
including platelet aggregation and leukocyte adhesion and
migration into vascular wall [51].
Interestingly, over the well-known involvement of NO in
the main cardio- and cerebrovascular diseases, other minor
vascular forms of vascular diseases had been associated with
impairment of the NO signaling. In this regard, it has been
widely recognized that NO plays a key role in the physiology
of penile erection eliciting its effect on guanylate cyclase lead-
ing to the production of cGMP. About this mechanism, the
impairment of NO activity is similar to that observed in other
forms of vascular diseases or in patients with cardiovascular
risk factors (e.g., dyslipidemia, diabetes, and hypertension)
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Figure 3: eNOS alteration, a common mechanism in different vascular diseases. The figure summarizes the main mechanisms of eNOS
dysfunction promoted in the main cardiovascular diseases (see text for details).
[52]. Another form of vascular alteration in which changes
in NO production and bioavailability have been reported
is represented by varicose vein disease [53]. Furthermore,
recent studies have found a link between endothelial dys-
function and NO alterations in venous valve dysfunction
[53]. In particular, processes associated with varicose vein
disease are increased destruction of collagen and matrix
proteins triggered by endothelial dysfunction, which in turn
is characterized by loss of NO bioavailability and increase
of inflammation and ROS build-up [54]. Based on these
findings, it is imperative to identify a new therapeutic strategy
aiming at stimulating NO production and preventing the
reduction of its bioavailability.
3.1. NO in Ischemia and Heart Failure. Many studies in
animal models have documented the existence of a link
between NO pathway impairment and CVDs. Kuhlencordt
et al. showed that atherosclerosis, aortic aneurysm formation,
and ischemic heart diseases can be accelerated as result of a
chronic deficiency of eNOS [55]. The authors compared the
atherosclerotic lesions occurring in two different knockout
(KO) animal models, apolipoprotein E (apoE)/eNOS-double
knockout (DKO) and apoE-KO, demonstrating that a genetic
deficiency of eNOS significantly increased atherosclerosis
in the apoE-KO mouse model. Of note, the location of
the lesions, occurring mainly in the areas with disturbed
flow, was similar in both KO models; therefore, the authors’
conclusion was that the absence of eNOS did not determine
the site of lesion formation in the aorta but appeared to
accelerate its development. In addition, the ApoE/eNOS-
DKO animals showed a more marked increase in blood pres-
sure, comparable to that of eNOS-KO mice, indicating that
eNOS deficiency could reflect different degrees of endothelial
dysfunction. These findings are very important because
they suggested eNOS deficiency/endothelial dysfunction as
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a possible molecular mechanism linking hypertension to
atherosclerosis [55].
Actually, Huang et al. have already demonstrated that
in mice lacking the gene encoding eNOS the acetylcholine-
induced relaxation was absent and the eNOS mutant mice
had elevated blood pressure and developed hypertension
[56].
Anti-ischemic actions of NO were also demonstrated
by using of a transgenic (TG) mice model with cardiac
specific overexpression of iNOS. After ischemia induced by
coronary occlusion followed by 24 hours of reperfusion, the
TG mice had a smaller infarct size compared to wild type.
In addition, iNOS overexpression was able to attenuate the
ROSs generation associated with reperfusion injury, in fact,
the quantity of the ROSs trapped from reperfused hearts
was lower in iNOS-TG than in wild type mice [57]. In
another study performed in amodel of eNOS-TGmice, it was
demonstrated that a cardiomyocyte-specific overexpression
of eNOS improved left ventricular performance and reduced
compensatory hypertrophy after myocardial infarction (MI).
Importantly, eNOS cardiac overexpression attenuated also a
post-MI remodeling by reducing fibrosis in the noninfarcted
area of the myocardium [58]. The beneficial role of the
eNOS-derived NO has been demonstrated also in congestive
heart failure (HF) in the study by Jones et al. in which the
authors, by using a mouse model of infarct-induced HF,
showed that eNOS overexpression enhanced animal survival,
inhibited pulmonary edema, and improved cardiac function
but did not attenuate the cardiac hypertrophy or improve
cardiac contractility [59]. Moreover, it has been reported that
the mitochondrial production of NO by mtNOS is reduced
during ischemia because there is a lack of the O
2
, necessary
to generate the NO [36].
These findings demonstrated that strategies aimed at
increasing NO bioavailability in the heart might be useful to
counteract the structural and functional damage induced by
myocardial ischemia.
3.2. NO in Diabetes and Atherosclerosis. NO production is
reduced in diabetes mellitus and atherosclerosis, well-known
risk factors for CVDs. In obese mouse model, eNOS activity
was reported to be reduced by an enhanced phosphorylation
at threonine 495 via PKC [60]. Similarly, Kashiwagi et al.
showed that the lack of phosphorylation at serine 1176 residue
was correlated with the development of obesity and insulin
resistance in a mouse model [61].
Uncoupling eNOS also concurs to develop diabetes mel-
litus and, as mentioned above, both oxidation of BH
4
and
depletion of L-arginine are the cause of such phenomenon.
In addition, BH
4
was shown to be oxidized in diabetic mouse
models, by a mechanism involving the activation of NADPH
oxidases through PKC [62]. Similarly, in diabetic hyperten-
sive rats, Alp et al. showed low levels of BH
4
and decreasing
in NO production [63]. Heitzer and colleagues demonstrated
that a supplementation of BH
4
improved endothelium-
dependent vasodilation in patients with type II diabetes
but not in control subjects. Of note, such beneficial effect
was completely blocked by N(G)-monomethyl-L-arginine,
a well-known inhibitor of NOS, suggesting that it was
dependent on the NO production increase [64].
Also L-arginine deficiency has been reported in diabetic
rats with a concomitant increase of the expression and
activity of arginases, particularly, arginase, which has been
recognized as the isoform responsible for eNOS uncoupling
in diabetes [65]. In this regard, diabetic mice deficient of
arginase I exhibited less endothelial dysfunction compared to
wild type mice [66]. Notably, in the same way, in coronary
arterioles of diabetic patients, arginase I was shown to
contribute to the reduction of vasodilatation [67], and in
plasma of patients with type II diabetes, arginase activity was
reported to be elevated [68].
Interesting data in both humans and animal model
have remarked the involvement of NO metabolism in the
atherosclerosis. For example, depletion of BH
4
has been
demonstrated in hypercholesterolemic patients [69] and high
level of superoxide anions produced by uncoupled eNOS
and increased formation of aortic atherosclerotic plaque with
the concomitant deficiency of BH
4
were found in ApoE-KO
mice where there were also observed an increased arginase II
expression and activity [70]. Similarly, in human endothelial
cells exposed to thrombin, Yang et al. found an enhancement
of the arginase enzymatic activity [71]. In ApoE-KO mice,
Ming et al. demonstrated that the small G protein RhoA and
its effector ROCK play a role in the regulation of arginases
activity involved in atherosclerotic process [72]. Moreover,
posttranslationalmodifications of the eNOShave been shown
to play a crucial role during atherosclerosis and diabetes
[73]. Importantly, recent investigations have highlighted that
phosphorylation and acetylation of the eNOS might concur
to mediate the beneficial effects of some drugs. In this
regard, Romero et al. have investigated the effects of BM-
573, a compound that combines thromboxane synthase inhi-
bition and thromboxane receptor antagonism, on endothelial
dependent relaxation during early stage of atherosclerosis in
apoE-KOmouse model. The authors demonstrated that BM-
573 was able to ameliorate endothelial dysfunction by reduc-
ing oxidative stress and improving the NO bioavailability
by increasing the eNOS phosphorylation [74]. Moreover, it
has been demonstrated that lysine acetylation of the eNOS
mainly contributes to the well-known atherothrombotic
effects of low-dose acetylsalicylic acid [75].
The eNOS posttranslational modifications are necessary
also in mediating the antidiabetic effects of several thera-
peutic interventions. For example, a diet supplementation
with l-arginine and sepiapterin along with salsalate has been
proved to increase the eNOS phosphorylation and improved
vasorelaxation of thoracic/abdominal aorta in type-1 diabetic
mice [76]. Furthermore, Ding et al. showed that cardiac
overexpression of SIRT1, a NAD+-dependent deacetylases,
reduced diabetes-exacerbated myocardial ischemia reperfu-
sion injury and oxidative stress in diabetic rats via eNOS
activation and that such effect was mediated by increase
of the eNOS phosphorylation and reduction of the eNOS
acetylation [77]. It has been also showed that the eNOS
phosphorylation might be also important in mediating the
beneficial effects of metformin and thiazolidinediones into
microvasculature. In this regard, Ghosh et al. demonstrated
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that a brief 3 h exposure to metformin induced changes in
eNOS signaling in mouse microvascular endothelial cells by
reducing the ratio of phosphorylated (p-eNOS)/eNOS, but
not the expression of total eNOS [78].
Xu et al. investigated the effects of ciglitazone in rat
microvascular endothelial cells, finding that such antidiabetic
drug was able to reverse the decrease of eNOS levels in the
cells stressed with oxidized LDL thus improving the NO
bioavailability [79].
3.3. NO and Hypertension. A decreased NO bioavailability
is one of the mechanisms involved in the pathogenesis of
hypertension. Indeed, the phosphorylation of eNOS at thre-
onine 495 residue was shown to be enhanced in angiotensin
II- (Ang II-) induced hypertensive rats [80]. Landmesser
et al. showed an increase of BH
4
oxidation caused by the
activation of the p47phox subunit of NADPH oxidase in
a model of salt-induced hypertension rat [42]. A similar
enhanced expression ofNAPDHoxidase has been also shown
in spontaneously [22] and in angiotensin II-induced hyper-
tensive rats [81]. In addition, an oral administration of BH
4
was shown to suppress the hypertension in spontaneously
hypertensive rats thanks to the reduction of ONOO− and
O
2
− accumulation [82]. Similarly, a supplementation of BH
4
increased acetylcholine-dependent endothelium vasodilata-
tion in hypertensive patients to the level of normal control
subjects [83].
Besides the oxidation of BH
4
, the depletion of L-arginine
could contribute to hypertension causing eNOS/NO impair-
ment. Indeed, in spontaneously hypertensive rats, as well as in
the aorta of mineralocorticoid and salt-induced hypertensive
rats, the expression/activity of arginases was found to be
enhanced [84–86]. Moreover, angiotensin II, via stimulation
of AT
1
, receptor is reported to be a molecular pathway
responsible for the increased expression/activity of arginases
in hypertension. In particular, in arginases knockout mice
Shatanawi et al. showed that the p38 MAPK is the down-
stream effectors of AT
1
, leading to endothelial dysfunction
[87]. Intravenous administration of L-arginine produces a
vasodilatory effect by increasing theNOproduction in hyper-
tensive individuals [88], as well as the arginase inhibitor N-
(omega)-hydroxy-nor-l-arginine prevents the hypertension,
lowering the blood pressure in a hypertensive rat model
[89, 90].
3.4. NO and Cerebrovascular Diseases. Several experimental
evidences have underlined the protective role of eNOS/NO
pathways in neuronal injury after cerebral ischemia as well
as in the prevention of stroke and severe subarachnoid
hemorrhage (SAH) [91, 92].
In physiological conditions, eNOS-derived NO is the
main molecule responsible for the control of the cerebral
blood flow (CBF). In this regard, it has been shown that
ischemic injury increases eNOS activity and NO availability,
which in turn leads to the improvements of the CBF and
to decreasing neuronal injury [93]. Osuka et al. [94], in rat
cerebral models of ischemia, found increased level of phos-
phorylation at eNOS Ser1177 residue in microvessels, with
temporary expression of VEGF. Similarly, in eNOS knockout
mice, aftermiddle cerebral artery (MCA) occlusion,Huang et
al. demonstrated an enlargement of infarct size and showed
that systemic administration of nitro-L-arginine prevented
brain damage [43].Moreover, thrombotic cerebral infarctions
have been found in eNOS+/− mice after three–six months
of age [95]. Other authors underlined the importance of
NO in the angiogenesis and neurogenesis occurring after
cerebral stroke; for example, neovascularization after stroke
was found to be impaired in eNOS deficient mice, indicating
that endothelial NO mediates this effect [96].
4. Main Modulators of NO Pathways
Several therapeutic strategies have been proposed to amelio-
rate the NO homeostasis. Currently, the best strategy is based
on the drugs administration in order to activate downstream
effectors of eNOS/NO from one side and to reduce eNOS
uncoupling [16], improving BH
4
and L-arginine bioavailabil-
ity and regulating post-translational modifications of eNOS,
from the other side. Nevertheless, it is important to remark
that a helpful strategy for the prevention and attenuation of
CVDs is to make a good lifestyle and, in this context, physical
exercise and specific diets such as diet rich in polyphenols
have been suggested to improve the NO pathways.
The inhibition of the renin-angiotensin-aldosterone sys-
tem is widely recognized as an effective therapy in CVDs [97].
In animal models, angiotensin-converting enzyme inhibitors
(ACE-I) and AT1 receptor blockers (ARBs) are able to reduce
eNOS uncoupling, while restoring BH
4
bioavailability [98],
and to protect against cerebral ischemia via upregulation of
the eNOS in middle cerebral artery [99] and cerebral infarct
size via eNOS activation [100].
The renin-angiotensin system blockers exert also
NO-dependent antithrombotic effects. In this regard,
Kucharewicz et al. demonstrated that angiotensin 1–7, a
component of the renin-angiotensin system, caused an
increased production of NO, which contributes to reduction
of thrombosis in rats [101].
Also the cholesterol-lowering drugs, the statins, improve
endothelial functions by enhancing the NO bioavailabil-
ity thanks to their antioxidant, anti-inflammatory, and
antiatherosclerotic properties [102, 103]. For example, in
hypercholesterolemic patients treated with fluvastatin, John
et al. demonstrated an improvement of endothelial vasodi-
latation through increase of the NO production [104]. More-
over, in a rat experimental model of MI, statins were found
to enhance NO bioavailability by restoring mobilization
of EPCs, myocardial neovascularization, and, ultimately,
increasing survival [42] and statins were also showed to
decrease eNOS uncoupling through a reduction of vascular
O
2
∙− and BH
4
oxidation [105].
Another way to ameliorate endothelial homeostasis is
the activation of the 𝛽-adrenoreceptor subtype 3 (𝛽
3
), which
leads to eNOS activation and thus to the NO generation
by increasing the levels of cAMP and Ca2+ [30, 31, 106].
Nebivolol, a third-generation 𝛽-adrenoreceptor blocker, is a
promising drug able to improve NO pathways thanks to its
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ability to antagonize 𝛽
1
and to activate 𝛽
3
receptors. Maffei
et al. [107] showed that nebivolol induced endothelial NO
production in both conductance and resistance rats arteries
in a calcium-dependent manner. In another study, the same
authors measured in mice the heart production of the NO
consequent to the stimulation of 𝛽
3
receptor and iNOS
increased activity, thus indicating nebivolol as therapeutic
strategy for hypertension and heart failure [108].
Another aspect that deserves attention is the link between
adrenergic pathway, NO bioavailability, and oxidative stress
and, in this context, the beneficial effects of the nebivolol
are attributable to its well-recognized antioxidant properties,
which are considered an additional factor for increasing
the NO bioavailability. For example, nebivolol and atenolol
(a second-generation 𝛽-blockers) similarly reduced blood
pressure values in hypertensive patients, but oxidative stress
markers, such as LDL hydroperoxides, 8-isoprostanes, and
ox-LDL were significantly improved only in patients treated
with nebivolol [109, 110].
Moreover, in hypertensive patients, Okamoto et al.
demonstrated that nebivolol lowered blood pressure [111],
while in elderly patients with heart failure it was shown to
reducemortality andmorbidity [112]. Interestingly, Falciani et
al. highlighted also the role of nebivolol in inhibiting platelet
aggregation by increasing L-arginine/NO, remarking also an
antithrombotic effect of this 𝛽-blocker [113].
Nowadays, researchers are paying particular attention
to the nonpharmacological strategies, including adoption of
specific diet habits and exercise programs for the manage-
ment of several chronic diseases.
In this context, several experimental and epidemiological
findings have underlined the role of physical exercise (PE)
in decreasing the oxidative stress associated with aging and
in the prevention and attenuation of CVDs-associated risk
factors [114–117]. It was suggested that the reduction of
oxidative stress triggered by PE could be associated with
the improvement of the NO function [118]. In this regard,
in patients with chronic heart failure and coronary artery
disease, Laurent et al. showed that water-based exercises
increased NO metabolism by improving cardiorespiratory
capacity and endothelial function [119]. Recently, a regular
exercise was demonstrated to activate eNOS and nitrite
production and to reduce oxidative stress in spontaneously
hypertensive rats [120]. PE was also suggested to have a
cardioprotective effects; in ischemic rats, high-intensity inter-
val training increased NO metabolites levels and reduced
myocardial infarction [121].
Different molecular mechanisms, such as phosphory-
lation status and transcription rate of eNOS, have been
proposed to explain the effects of PE on the NO production.
For example, in rats subjected to acute and chronic aerobic
training eNOS mRNA levels were found to be upregulated
[122]. Other authors underlined the role of 𝛽
3
adrenoreceptor
in mediating the effects of PE on the NO production; in
particular, Calvert et al. demonstrated that exercise could
improve the cardiac function in ischemic rats via𝛽
3
adrenore-
ceptor by increasing the eNOS phosphorylation [123].
Anothermolecularmechanism is represented by theNO-
dependent changes in the vascular redox state and oxidative
stress even if the beneficial role of the NO in this context
could be complex to elucidate. In this regard, Farah et al.
suggested that certain level of eNOS uncoupling could be
required for exercise-induced myocardial cardioprotection
during ischemia reperfusion. In particular, in such study,
it was showed that eNOS uncoupling was associated with
the improvedmyocardial antioxidant capacity that prevented
excessiveNO synthesis limiting the reaction betweenNOand
O
2
∙− to form peroxynitrites [124].
5. Crosstalk between NO and
the Other Gasotransmitters
Besides the NO, other two gaseous molecules, hydrogen sul-
fide (H
2
S) and carbonmonoxide (CO), have been recognized
as “gasotransmitters” [125]. Much like their predecessor NO,
H
2
S and CO have been historically considered as highly toxic
and harmful agents; afterward, many investigations have
showed that they not only play various physiological roles
but could be effective against a number of diseases, including
CVDs [126].
Indeed, also CO and H
2
S mediate muscle relaxation and
vasodilatation, the first, as well as the NO, through activation
of GMP and consequent elevation of cGMP levels and the
second through a cGMP-independent mechanism [127, 128].
Compelling evidence has demonstrated that each mem-
ber of this triad of gasotransmitter can influence each other.
For example, the inhibition of the NO synthesis might
increase the CO production [129], while low-dose CO has
been showed to decrease the eNOS mRNA expression [130].
Recently, particular attention is paid to the role of
crosstalk existing among the gasotransmitters in determining
cytoprotective effects in the heart and vessels. It was demon-
strated that NO, CO, and H
2
S act in concert to preserve
the cardiovascular homeostasis thanks for instance to their
antioxidant and anti-inflammatory properties [131].
Noteworthy, the gaseous nature of these compounds
makes them attractive candidates for the treatment of sev-
eral pathological conditions, especially ischemia reperfusion
injury. In this regard, H
2
S have been shown to stimulate
vascular remodeling after ischemia in mice by enhancing
the NO production [132]. Donnarumma et al. have recently
investigated in murine and swine models of ischemia reper-
fusion the effects of an oral administration of zofenopril, an
ACE-I containing a sulfhydrylic group. The authors found
that zofenopril reduced myocardial infarct size in both
animal models and preserved blood flow in swines and such
effects were associated with an elevation of the H
2
S and NO
plasmatic levels [133].
Importantly, there are conflicting evidences on the anti-
ischemic effects of the ACE-I and some studies have revealed
such effects only for sulfhydryl-containing agents [134].
Moreover, it was demonstrated that an early treatment of
the acute myocardial infarction with zofenopril is able to
reduce morbidity and mortality any more than ramipril,
dicarboxylate-containing ACE-I [135].
Therefore, the understanding of themechanisms involved
in the cytoprotective effects of all gasotransmitters either
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individually or together is necessary to fully exploit their
therapeutic potential.
6. Natural Derived Compounds and NO
Growing evidence leads to considering a healthy dieting
regimen as an helpful strategy to reduce CVDs-associated
risk factors acting, as well as the aforementioned drugs, via
modulation of the NO pathways.
The Mediterranean diet, rich in fruits and vegetables
and based on high consumption of red wine, was associated
with a good prognosis in patients with CVDs [136–139]. In
particular, in subjects who usually consume large amounts
of fruits, vegetables, red wine, tea, chocolate, and nuts, a
significant improvement of endothelial function has been
reported, which in turn contributes to reduction of blood
pressure, atherosclerosis, and cardiovascular mortality [140,
141]. Interestingly, the beneficial properties of the red wine
were recognized as the solution of the “French paradox,”
a term used to describe the observation that the French
population had a low incidence of CVDs, despite a diet
predominantly characterized by a high consumption of wine
and saturated fat food [142]. The protective effects against
CVDs have been attributed, at least in part, to the high
content in these specific foods of polyphenols, a class of
chemicals characterized by the presence of phenol units in
their chemical structure [143].
6.1. Classification and Source of Polyphenols
6.1.1. Flavonoids. Flavonoids represent a large group of
polyphenols, characterized by two benzene rings linked via
a heterocyclic pyran ring.The latter gives reason of the differ-
ences between the various classes of flavonoids. According to
their chemical structure, the flavonoids can be subdivided in
(i) flavones, such as apigenin (bilberry, raspberry, strawberry,
plum, cherry, blackberry, red pepper, and tomato skin)
[144], (ii) flavonols that include quercitin (red onions, tea,
wine, apples, cranberries, buckwheat, and beans) [145], (iii)
isoflavones, including genistein (soy, legumes) and coume-
strol (soy, red clover), also known as phytoestrogens [146],
and (iv) flavanols that include catechins and epicatechin
(tea, apple juice, wine, and cocoa) [147]. Interestingly, these
compounds have been found also in medical plants, such as
Aloe vera [148] and Cannabis sativa [149]. Flavonoids have
been demonstrated to exert a plethora of beneficial effects
both in vivo and in vitro and to regulate specific molecular
pathways and target several genes [150, 151]. In particular,
the best characterized biological property for all flavonoids,
as well as for polyphenols in general, is their ability to act
as antioxidants, inhibiting ROS accumulation, acting either
by scavenging ROS or inhibiting enzymes involved in the
ROS production or by enhancing the natural antioxidant
defenses [152]. Moreover, several studies have shown and are
underlining anticancer activities of the flavonoids. For exam-
ple, quercitin has been shown to inhibit cell proliferation in
several human cells, such as lymphoid, colon, ovarian, and
gastric cells, through modulation of several genes involved
in cancer progression [153]. Moreover, genistein has been
recently proposed as a chemopreventive agent especially
against prostate cancer, thanks to several interesting results
deriving from in vitro and epidemiological studies [154, 155].
6.1.2. Stilbenoids. Stilbenoids are a class of phenolic com-
pounds synthesized as defense agents from the plants
expressing stilbene synthase. Resveratrol is the most stud-
ied stilbenoid, but more than 400 compounds have been
identified; most of them are currently used in Chinese
traditional medicine [156]. Generally, stilbenoids are clas-
sified on the basis of the number of the C6-C2-C6 units
(monomer, dimers, trimers, tetramers, and examers). They
are present abundantly in berries (grape, blueberry, bilberry,
cowberry, cranberry, and strawberries) and peanuts but are
also detectable in cocoa powder, dark chocolate, and white
tea [157, 158]. As mentioned for the flavonoids, several
researches have suggested a role of stilbenoids as anticancer,
antioxidant, and antiaging agents or as positive modulators
of several human degenerative diseases [159, 160]. In this
regard, resveratrol has been shown to induce apoptosis in
breast cancer and prostate cells, by induction of caspases,
Bax proteins, and p53 [161, 162]. Of note, a natural analog of
resveratrol has been documented to inhibit growth of several
cancers, such as pancreatic [163] and colon [164] cancer.
6.1.3. Curcuminoids. Cucrcuminoids are chemical com-
pounds extracted from the rhizome of Curcuma Longa Linn.
They are characterized by a linear structure (diarylheptanoid)
with two phenolic groups (C6-C7-C6) and are widely used
as colorants for vegetables. Curcumin and its derivates have
been demonstrated to possess numerous pharmacological
activities, including anti-inflammatory, antioxidant, and anti-
tumorigenic effects. In particular, it has been reported that
curcumin is able in vitro to downregulate the expression of
cyclin D and E and to upregulate p53 and p21, which in
turn contribute to arresting cell proliferation/migration and
promoting apoptosis [165, 166]. Concerning its antioxidant
properties, curcumin acts prevalently as superoxide radical
scavenger [167].
6.1.4. Phenylethanoids. Phenylethanoids are polyphenols
characterized by a phenethyl alcohol structure. Typical
examples of phenylethanoids are tyrosol and its derivate
oleuropein, present prevalently in olive oil and olive leaf.
Oleuropein is the most abundant polyphenol in olives and
thus it is receiving particular attention by the scientific
community because extra virgin olive oil is an essential
component of Mediterranean diet. Several studies have
demonstrated that the oleuropein possesses a wide range of
pharmacological properties such as antiatherogenic [168],
hypotensive [169], and antidiabetic [170], as well as anticancer
activity and antioxidant effects [171, 172]. Moreover, also
hydroxytyrosol, a metabolite of oleuropein, has been shown
to possess antioxidant properties [173] as well as anti-
inflammatory, antiplatelet aggregation, antiatherogenic and
cardioprotective, antimicrobial, antiviral, and anticancer
activities [174].
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Figure 4: Natural derived compounds increase NO production: a
diet rich in polyphenols, deriving fromdifferent sources, contributes
to counteract oxidative stress and enhances NO generation, so
improving the endothelial function.
7. Polyphenols and the NO Signaling
Concerning the effects on vascular physiology, several data
suggest that polyphenols act on the NO signaling and
metabolism, improving eNOS expression and activity, as
well as reducing eNOS uncoupling. Nowadays, one of the
limits during the characterization of the molecular pathways
activated by polyphenols is that most of the experiments
have been conducted with the total extracts of food, such as
wine, cocoa powder, or olive leafs extracts; therefore often it
is very difficult to identify the specific compound exerting
protective effects. Nevertheless, some studies measured the
effects of single compounds, such as resveratrol, quercitin,
or curcumin [175]. Irrespective of their source, one of the
main effects exerted by the polyphenols is the NO-dependent
vasodilatation (Figure 4). For example, in isolated arteries
of rabbits, Karim et al. demonstrated that cocoa extracts
increased levels of intracellular Ca2+, leading to L-arginine
conversion in citrulline and to the eNOS activation [176].
Similarly, plant-derived polyphenols have been reported to
induce vasodilatation of porcine coronary arteries through
NO generation [177]. Moreover, in bovine endothelial cells,
catechins of green tea activated eNOS by phosphorylation
at Ser1179 and dephosphorylation at Thr495 in a PKA-Akt
dependent manner [178, 179]. In addition, such compounds
were also shown to exert protective effects in diabetic
rats thanks to the reduction of oxidative stress obtained
by downregulation of NADPH oxidase [180]. Interestingly,
catechins were found to reduce platelet aggregation and to
reverse endothelial dysfunction in patients with coronary
artery disease, thus exerting antiatherosclerotic properties
[181, 182]. Moreover, polyphenols of the black tea were
found to enhance the activity of eNOS via p38 MAPK-
dependent phosphorylation in porcine aortic endothelial
cells. In fact, both pharmacological and genetic inhibition of
p38MAPK attenuated both eNOS activation and phosphory-
lation changes in response to these polyphenols [183].
Among plant-derived polyphenols, fruit extracts of
Camelia japonica (CJF), a plant widely distributed in Asia
andwell known for its antioxidant properties [184], have been
demonstrated to induce the NO production via Akt pathways
in endothelial cells and to activate eNOS via phosphorylation
at Ser1179. In the same study, CJF inhibited VSMCs prolif-
eration and migration, suggesting its beneficial role in the
prevention of atherosclerosis [185]. Similarly, polyphenols of
the tropical plant Terminalia have been reported to induce a
calcium-dependent activation of eNOS [186].
Interestingly, Appeldoorn et al. by using an in vitro
screening to discover the potential effects of different
polyphenols have found that quercitin, abundant in many
vegetables and fruits, is one of themajor stimulator of the NO
production [187]. Indeed, the effects of quercitin have been
extensively investigated in animalmodels of CVDs, especially
with regard to its antihypertensive effects. For example, a
reduction of blood pressure after administration of quercitin
in spontaneously hypertensive rats has been showed [188],
as well as in salt-hypertensive [189, 190] and NO deficient
rats [191]. Recently, it has been reported that quercitin is able
to ameliorate arterial erectile dysfunctions in rats via NOS
regulation restoring, almost in part, the function of NO-
cGMP pathway in the process of penis erection [192].
The molecular mechanism involved in the antihyperten-
sive effect of the flavonoid quercitin was attributed to the
inhibition/downregulation of NADPH oxidase. Concerning
this, Perez-Vizcaino et al. demonstrated that quercitin was
able to induce the lowering of blood pressure by diminishing
superoxide-driven NO inactivation via downregulation of
aortic p47phox, a regulatory subunit of NADPH oxidase,
which is the main source of vascular superoxide [193].
These results are in accordance with others showing that
quercitin decreased NADPH oxidase-mediated superoxide
anion generation, as a consequence of inhibition of p47
protein subunit expression in [194].
In isolated rat aortic ring, Jin et al. found that api-
genin, a polyphenol abundant in many plants, enhanced
the NO bioavailability via reduction of oxidative stress.
Apigenin evoked a concentration-dependent relaxation in
aortas, which was specifically inhibited by L-NAME, a direct
inhibitor of NOS. Of note, vasodilation occurred concomi-
tantly with inhibition of superoxide anion and increasing of
the NO levels [195]. In a similar way, curcumin has been
reported to increase relaxation in porcine coronary arteries,
probably thanks to mechanism involving NO, cGMP, and
adrenergic 𝛽-receptor and, also in this case, such relaxant
effect was specifically inhibited by L-NAME [196].
The involvement of caveolin-1 in polyphenols-mediated
effects on the NO pathways has also been reported. Li et
al. demonstrated in endothelial cells that green tea extracts
downregulated the caveolin expression via activation of
ERK and deactivation of p38 MAPK kinases [197]. Simi-
larly, Vera et al. found in hypertensive rats that genistein,
a soy isoflavone, was able to enhance eNOS activity via
inhibition of caveolin-1 and NADPH oxidase and favoring
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O
2
− reduction, thereby leading to decrease in blood pressure
[198]. Moreover, soy isoflavones has also been demonstrated
to improve the NO metabolism in carotid and cerebral rat
arteries [199] as well as to enhance eNOS mRNA expression
[200].
NO-mediated antihypertensive effects were also reported
in rats after administration of other soy isoflavones, such as
glucosyl hesperidin [201]. Yamamoto et al. found that the
hypotensive effects of this natural compound were associated
with reduction of oxidative stress and improvement of the
NO metabolism [202]. In this regard, hesperidin was found
to significantly prevent endothelial damage and leucocytes
adhesion in animal models of ischemia reperfusion. Con-
comitantly, an increase of NO bioavailability and a reduction
of inflammatory molecules which contribute to ameliorate
edema and other symptoms of venous diseases have been
reported [203].
Polyphenol-rich cocoa extracts have been demonstrated
to reduce blood pressure in spontaneously hypertensive rats
[204] and, similarly, in hypertensive patients, as well in
healthy subjects, the intake of black cocoa extracts has been
reported to reduce blood pressure and improve endothelial
function through increase of the NO bioavailability [205–
208]. Moreover, in patients with high cardiovascular risk it
was showed that the administration of two different diets,
one rich in polyphenols deriving from extra virgin olive oil
and another rich in nuts, was shown to reduce systolic and
diastolic pressure concomitantly with an increase of the NO
plasma levels [209].
7.1. RedWine Polyphenols and NO Pathways. Red wine is one
of themain sources of the natural polyphenols. Asmentioned
above, epidemiological studies have suggested that the high
consumption of red wine correlates with a reduction of
the CVDs risk factors. The evidence corroborating vascular
effects of red wine polyphenols (RWPs), as well as grape seed
extracts (GSEs) and grape juice polyphenols (GJPs), is the
induction of NO-dependent relaxation in isolate arteries and
the activation of NO signaling pathways in endothelial cells
[210–212]. Leikert et al. found that RWPs enhanced eNOS
expression and release of NO in human endothelial cells
[213]. In the same way, NO production and intracellular Ca2+
release have been shown in bovine endothelial cells treated
with RWPs [214] and an increase of eNOS and Akt phospho-
rylation were also reported in endothelial cells exposed to
GSEs [215]. Similar eNOS activation was also demonstrated
in isolated arteries. For example, in porcine coronary arteries
Madeira et al. showed endothelium relaxation induced by
GSEs via Akt/eNOS phosphorylation [216], and also in iso-
lated porcine coronary arteries, RWPs were found to enhance
phosphorylation of eNOS at Ser1177, resulting in the increase
of the NO production [217]. Interestingly, in rat femoral
arteries, RWPs were shown to induce vasodilatation and to
increase the NO levels in a concentration-dependent manner
[218]. Moreover, RWPs were demonstrated in rat aorta to
enhance NO bioavailability and to increase intracellular Ca2+
and cGMP concentrations [218, 219].
Several molecular mechanisms have been proposed to
explain in both animal models and humans the beneficial
effects of the RWPs in vascular physiology. In this regard,
Berna´tova´ et al. in hypertensiveNOdeficient rats showed that
RWPs restored endothelial functions thanks to a reduction of
blood pressure induced by increased eNOS activity in the left
ventricle and aorta [220].
Similarly, in salt-induced hypertensive rats, RWPs were
shown to improve vascular physiology by inhibiting NADPH
oxidase [221]. The inhibition of NADPH oxidase was also
reported in Ang II hypertensive rats treated with RWPs
in which a reduction of superoxide anions level occurred
concomitantly with restoration of the NO bioavailability
[222]. RWPs have been demonstrated to exert protective
effects also in animal models of ischemia and atherosclerosis.
For example, in ischemic rats, RWPs were shown to reduce
the angiogenic process [223], and, in hypercholesterolemic
mice, Napoli et al. showed that low doses of RWPs reduced
atherosclerosis by eNOS activation [224]. Interestingly, with
an in vitro model of human atherosclerosis, Magrone et
al. have reported enhanced production of the NO, after
administration of red wine. The authors tested some red
wines for their ability to trigger NO production from human
healthy peripheral blood mononuclear cells, finding that
flavonoids and resveratrol, abundant in the red wine, once
absorbed at intestinal level and entered into circulation,
induced monocytes to produce the NO [225].
Few clinical trials have plannedwith the aim to investigate
the effects of a dietary regimen based on moderate con-
sumption of wine about NO related improvement in vascular
physiology in both healthy patients and patients with high
risk ofCVDs. For example, in healthy subjects, an oral supple-
mentation of grape juicewas found to inhibit platelet aggrega-
tion with decreased production of superoxide and enhanced
NO levels [226, 227]. Moreover, besides its antithrombotic
activity, red wine has also been suggested to exert cardiovas-
cular protective effects by enhancing circulating endothelial
progenitor cells thanks to a mechanism involving an increase
of the NO bioavailability, as reported in studies performed
in healthy individuals by Huang et al. [228]. In addition, red
wine consumption has been shown to significantly decrease
bloodpressure and enhance plasmaNO levels in hypertensive
patients [229]. Interestingly, Karatzi et al. demonstrated that
in smokers a consumption of red wine counterbalanced the
endothelial dysfunction caused by oxidative stress induced
by cigarettes smoke, in a pathway probably mediated by NO
[230].
7.2. Resveratrol and NO Pathways. Among the RWPs, resver-
atrol (RSV) is one of the best characterized members. It has
been used in the Indianmedical herb named “Darakchasava”
from about 4500 years ago and the clinical effects described
in the past for “Darakchasava” are the same attributed to RSV
today [231]. RSV was firstly described for its antitumorigenic
properties [232]; it is present especially in grape skin and red
wine, but also in peanuts, pistachios, and pine trees [233].
The interest of the scientific community for RSV derives from
the observation that its administration mimics the effects of
calorie restriction, a tool widely recognized to prevent the
endothelial dysfunction, thereby attenuating atherosclerosis,
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hypertension, diabetes, and CVDs risk factors and aging-
associated diseases in general [234–236]. Thanks to some
experiments conducted in vitro in endothelial cells, RSV has
been shown to regulate several target molecules, such as
the NAD+-dependent deacetylases named sirtuins, acting at
transcriptional and posttranscriptional levels [237–239].
Although the studies underlining the vascular protective
effects exerted by RSV did not study the involvement of
the NO signaling [157, 234], several findings, obtained in
animal models of CVDs, have proposed the NO as the
main downstream target mediating such effects. For exam-
ple, Xia et al. demonstrated in ApoE deficient mice that
RSV was able to modulate the oxidative stress responsible
for atherosclerosis. From one side, NADPH oxidases were
downregulated; from the other side superoxide dismutases
(SOD) were upregulated. Moreover, oxidation of BH
4
was
found to be reduced, attenuating the increase of eNOS
uncoupling levels [240]. Other beneficial effects were shown
in many different clinical settings reinforcing the idea that
RSV could be considered an optimal therapeutic strategy
against CVDs. For example, in hypercholesterolemic rabbits,
RSV improved endothelial function in parallel with an
increase of NO plasma levels [241]. In addition, RSV has been
suggested to contrast the endothelial dysfunction correlated
with metabolic syndromes. In this regard, in endothelial cells
RSV was demonstrated to suppress superoxide generation
and to activate eNOS through phosphorylation at Ser1177
thereby increasing the NO generation [242]. In aortas of
diabetic mice, RSV restored vasodilatation by enhancing
eNOS activity and inhibiting the tumor necrosis factor 𝛼-
(TNF𝛼-) induced activation of NADPH oxidase [243]. In the
same way, a treatment in rats with RSV has been showed
to increase muscle microvascular recruitment via an NO-
dependent mechanism blocked by TNF𝛼 [244]. Also, RSV
was shown to reduce blood pressure in obese rats and to
enhance the expression of eNOS via AMPK and reduction
of TNF𝛼 in adipose tissue [245]. Similarly, in rats fed with
high fructose diet, RSV decreased blood pressure via AMPK-
Akt-NOS pathway [246]. Interestingly, in the myocardium
of diabetic mice, RSV reduced Cav-1 expression, which in
turn contributes to enhance eNOS activity [247], and the
same effects on Cav-1 expression were found in hypercholes-
terolemic rats [248].
Furthermore, RSV was shown to protect heart from
ischemic reperfusion injury. Hattori et al. demonstrated that
RSV reduced infarct size in rat hearts by enhancing iNOS
expression [249]. The cardioprotective effects of the RSV has
also been showed in spontaneously and angiotensin Ang II-
induced hypertensive rats, in which RSV contributes to the
upregulation of the eNOS activity and reduction of pressure
and cardiac hypertrophy [250]. Moreover, the antihyperten-
sive effect of the RSV was also shown to be mediated by the
attenuation of eNOS uncoupling via reduction of L-arginine
levels and oxidative stress [251].
The antithrombotic activity of the RSV has been also
reported in human platelets. Gresele et al. showed that RSV
stimulated platelet NO production through inhibition of p38
MAPK, NADPH oxidases, and superoxide formation, thus
decreasing peroxynitrite accumulation [252].
RSV was also shown to mobilize endothelial progenitor
cells in a NO-dependent manner, thus contributing to repair-
ing the damage occurring in vessels after ischemic injuries
[253].
In the arteries of patients with hypertension and dyslipi-
demia, Carrizzo et al. characterized many of the downstream
effectors of the RSV-dependent NO generation. The authors
found an enhanced vasodilatation of arteries due to the
activation of AMPK and reduction of eNOS uncoupling via
increasing levels of BH
4
and, in the same study, RSV was
found to reduce vascular oxidative stress trough upregulation
of manganese superoxide dismutase in a pathway mediate by
nuclear factor erythroid-derived 2-like 2 [254].
Some authors have also suggested the potential therapeu-
tic use of RSV for the prevention of stroke; for example, in
rat models of stroke, RSV reduced brain damage in a NO-
dependent manner [255]. Similarly, in rats subjected to focal
cerebral ischemia Tsai et al. provided the evidence that RSV
might enhance plasma levels of the NO and upregulate eNOS
expression while it might downregulate iNOS expression and
that these effects were abolished by the coadministration of
selective NOS inhibitors [256].
8. Bioavailability of Polyphenols
Although the use of the polyphenols represents a promising
tool for increasing the NO production and activity against
CVDs, one of the biggest challenges for their employ in the
clinical practice is to enhance their low bioavailability. In
this regard, it has been shown that when orally administered,
polyphenols concentration appears not to be sufficient to
ensure therapeutic effects [257]. For example, the plasmatic
levels of the resveratrol from dietary intake are often unde-
tectable or very low when compared with the concentrations
employed during in vivo and in vitro experiments [258].
Similarly, the pharmacological properties of curcumin are
drastically restrictedmainly because of its lowwater solubility
and absorption from the gut, short half-life, and extremely
poor bioavailability.
To overcome such problems, one of the best approach
could be developing new pharmaceutical formulations, for
example, polyphenols conjugated with cyclodextrins, or
encapsulated in nanoparticles (NP), such as poly(lactic-
co-glycolic acid) (PLGA) based NP or liposomes. In this
regard, many of these formulations have been demon-
strated to improve solubility, systemic half-life, resistance to
metabolic degradation, and ultimately the bioavailability of
the polyphenolic compounds in order to potentiate their
biological activities [259, 260].However, while the differences
between polyphenols monoadministered or administered in
encapsulated formulations have been extensively studied for
what concerns the polyphenols antioxidant and anticancer
properties, no experiments have been carried out on the
effects of these formulations on the NO metabolism.
9. Conclusion
Targeting the gasotransmitter NO is becoming a new chal-
lenge in cardiovascular medicine. We here reviewed some
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of the experimental evidences that have indicated several
natural compounds as suitable activators of the NO signaling
pathways.
It is necessary to remark that for most of them the
molecular mechanism, as well as the precise concentration
to obtain beneficial effects, especially because of their low
bioavailability remains to be determined. Nevertheless, these
agents, mainly the polyphenols, doubtless possess a great
therapeutic potential above all when you consider that the
available drugs, although effective, did not act exclusively
on the NO pathways often causing deleterious side effects.
Moreover, most of the investigations on the natural com-
pounds have involved in vitro studies; thus it is difficult to
draw definite conclusions about their therapeutic usefulness.
Although accumulating evidence suggests that the
polyphenols exert beneficial effects against vascular diseases
by restoring the impairment of the NO production and/or
bioavailability, much remains to be clarified. Doubtless, many
gaps must be filled in understanding the complex chemistry,
biochemistry, and molecular biology of such natural agents
in order to introduce such NO signaling modulators in the
clinical practice.
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